Aligos Therapeutics (ALGS) Total Liabilities (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Total Liabilities for 8 consecutive years, with $34.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 4.88% year-over-year to $34.4 million; the trailing twelve-month figure through Jun 2026 stood at $34.4 million (up 4.88% YoY), and the FY2025 full-year result was $35.0 million, down 64.68% from the prior year.
• Total Liabilities advanced to $34.4 million in Q2 2026 per ALGS's latest filing, from $32.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $99.1 million in Q4 2024 and bottomed at $31.0 million in Q3 2023.
• Historically, Total Liabilities has averaged $44.8 million across 5 years, with a median of $38.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities jumped 84.13% in 2024, then slumped 64.68% in 2025.
• Over 5 years, Total Liabilities stood at $42.8 million in 2022, then jumped by 38.92% to $59.4 million in 2023, then soared by 66.65% to $99.1 million in 2024, then tumbled by 64.68% to $35.0 million in 2025, then fell by 1.56% to $34.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $34.4 million, $32.8 million, and $35.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.